Prince Pharmaceutical Co., Ltd. (6935.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$27.25 (-4.39%) as of
Key statistics
- Market cap
- 1.29B
- P/E (TTM)
- 7.85
- EPS (TTM)
- 3.47
- Dividend yield
- 1.74%
- 52-week range
- 25.80 – 33.80
- Beta
- 0.61
- Revenue (TTM)
- 1.22B
- Profit margin
- 10.62%
- Volume
- 22.18k
About Prince Pharmaceutical Co., Ltd.
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin C tablets, vitamin B film-coated tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yunlin, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Yunlin, Taiwan
- Employees
- 216
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.